Management of primary central nervous system lymphoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 2, Issue 4, 2004, Pages 341-349

  El Kamar, Francois G ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain; Lymphoma; Methotrexate; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BRAIN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; RADIOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 29844451754     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2004.0028     Document Type: Article

References (72)

1. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-863.
2. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 1999;43: 203-208.
3. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000;181:1-12.
4. Bailey P. Intracranial sarcomatous tumours of leptomeningeal origin. Arch Surg 1929;18:1359-1402.
5. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-1510.
6. Cote TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996;88:675-679.
7. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Central Brain Tumor Registry of the United States, 2002. Available at www.cbtrus.org
8. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 2001;13:160-166.
9. Deangelis LM, Yahalom J, Rosenblum M, Posner JB. Primary CNS lymphoma: managing patients with spontaneous and AIDS-related disease. Oncology (Huntingt) 1987;1:52-62.
10. Herrlinger U, Schabet M, Bitzer M, et al. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 1999;43:219-226.
11. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999;26:346-356.
12. Buhring U, Herrlinger U, Krings T, et al. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-396.
13. Jenkins CN, Colquhoun IR. Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the literature with particular reference to calcification haemorrhage and cyst formation. Clin Radiol 1998;53:428-434.
14. Roelcke U, Leenders KL. PET in neuro-oncology. J Cancer Res Clin Oncol 2001;127:2-8.
15. Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 1999; 43:231-236.
16. Taylor CR, Russell R, Lukes RJ, Davis RL. An immunohistological study of immunoglobulin content of primary central nervous system lymphomas. Cancer 1978;41: 2197-2205.
17. Tuaillon N, Chan CC. Molecular analysis of primary central nervous system and primary intraocular lymphomas. Curr Mol Med 2001;1:259-272.
18. Gijtenbeek JM, Rosenblum MK, DeAngelis LM. Primary central nervous system T-cell lymphoma. Neurology 2001;57:716-718.
19. Camilleri-Broet S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 1998;110:607-612.
20. Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002;20:231-236.
21. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-272.
22. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-1104.
23. DeAngelis LM, J Y. Primary central nervous lymphoma. In: DeVita VT HS, Rosenberg SA, eds., ed. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:2330-2339.
24. Henry JM, Heffner RR Jr, Dillard SH, et al. Primary malignant lymphomas of the central nervous system. Cancer 1974;34:1293-1302.
25. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835-853.
26. Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997;115:1157-1160.
27. Miller DC, Hochberg FH, Harris NL, et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383-1397.
28. Herrlinger U. Primary CNS lymphoma: findings outside the brain. J Neurooncol 1999;43:227-230.
29. DeAngelis LM, Yahalom J, Heinemann MH, et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80-86.
30. Todd FD 2nd, Miller CA, Yates AJ, Mervis LJ. Steroidinduced remission in primary malignant lymphoma of the central nervous system. Surg Neurol 1986;26:79-84.
31. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999;43:237-239.
32. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
33. Berry MP, Simpson WJ. Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys 1981;7:55-59.
34. Hochberg FH, Loeffler JS, Prados M. The therapy of primary brain lymphoma. J Neurooncol 1991;10:191-201.
35. Hormigo A, DeAngelis LM. Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma 2003;4:22-29.
36. Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol 2002;13:411-418.
37. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000;11:927-937.
38. Stewart DJ, Russell N, Atack EA, et al. Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: a case report. Cancer Treat Rep 1983;67:287-291.
39. Shibamoto Y, Tsutsui K, Dodo Y, et al. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 1990;65: 1907-1912.
40. Lachance DH, Brizel DM, Gockerman JP, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994;44:1721-1727.
41. Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000;89:1359-1370.
42. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996;14:556-564.
43. Brada M, Hjiyiannakis D, Hines F, et al. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998;40:1157-1162.
44. Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997;8:227-234.
45. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-871.
46. Loeffler JS, Ervin TJ, Mauch P, et al. Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 1985;3:490-494.
47. Gabbai AA, Hochberg FH, Linggood RM, et al. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 1989;70:190-194.
48. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81: 188-195.
49. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-643.
50. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998;16:3000-3006.
51. Cheng AL, Yeh KH, Uen WC, et al. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 1998;82: 1946-1951.
52. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259-268.
53. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18: 3144-3150.
54. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60; discussion 60-61.
55. Ferreri AJ, Reni M, Dell'Oro S, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 2001; 60:134-140.
56. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-4648.
57. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21: 1044-1049.
58. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21:4483-4488.
59. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21: 4489-4495.
60. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of highdosemethotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999;91: 221-230.
61. Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175-178.
62. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcomedetermining factors in primary CNS lymphomas. Br J Cancer 2004;90:353-358.
63. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intentto-treat analysis. J Clin Oncol 2003;21:4151-4156.
64. Reni M, Ferreri AJ, Landoni C, Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 2000;92:575-576.
65. Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003;26:351-354.
66. Ciordia R, Hochberg F, Batchelor T. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma. Proc Am Soc Clin Oncol 2000:165a, Abstract: 639.
67. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer 1993;72:843-849.
68. Kessler LS, Ruiz A, Donovan Post MJ, et al. Thallium-201 brain SPECT of lymphoma in AIDS patients: pitfalls and technique optimization. AJNR Am J Neuroradiol 1998;19:1105-1109.
69. Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998;39:1366-1369.
70. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999;17: 554-560.
71. Tosi P, Gherlinzoni F, Visani G, et al. AZT plus methotrexate in HIV-related non-Hodgkin's lymphomas. Leuk Lymphoma 1998;30:175-179.
72. Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. Aids 1997;11:1725-1730.